October 25th 2024
Zanubrutinib, obinutuzumab, and venetoclax delivered promising response and survival data for the treatment of patients with mantle cell lymphoma harboring a TP53 mutation.
September 18th 2024
September 16th 2024
Options for Second-Line Treatment in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
July 23rd 2021Dr Laurie Sehn reviews the NCCN guidelines for second-line therapy in relapsed/refractory diffuse large B-cell lymphoma and discusses the clinical trial data for a recently approved new treatment combination.
Watch
Ibrutinib Bests Chlorambucil in Elderly Patients with Treatment-Naïve CLL/SLL
July 1st 2021Paul Barr, MD, discusses the results of the RESONATE-2, which evaluates efficacy of the Bruton’s tyrosine kinase inhibitor, ibrutinib versus chlorambucil in patients who are 65 years old or older with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Watch
FDA Approval Sought for Copanlisib Plus Rituximab in Relapsed iNHL
June 21st 2021A supplemental new drug application has been submitted to the FDA seeking approval for the combination of copanlisib and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin’s Lymphoma and is outside of the FDA accelerated approved indication for the treatment of relapsed follicular lymphoma who have received at least 2 prior systemic therapies.
Read More
Lenalidomide Added to Rituximab Following Resistance Leads to Progression Delay in Lymphomas
June 16th 2021Following rituximab resistance, the combination of lenalidomide and rituximab led to durable improvements in outcome for patients with indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas, even after 10 years of follow-up, according to long-term results presented at the European Hematology Association 2021 Congress.
Read More
Phase 3 Front-MIND Trial Initiated to Explore Tafasitamab Triplet in DLBCL
June 16th 2021A phase 3 trial has been initiated to explore the potential of a triplet regimen of tafasitamab-cxix, lenalidomide, and R-CHOP as a treatment options for patients with newly diagnosed diffuse large B-cell lymphoma.
Read More
Rituximab Maintenance Improves Time-to-Next Treatment and OS in Patients With Mantle Cell Lymphoma
June 14th 2021Time-to-next treatment and overall survival were improved in a real-world study evaluating patients who received rituximab maintenance after first-line treatment with bendamustine and rituximab or R-CHOP in patients with mantle cell lymphoma, according to a retrospective analysis presented at the European Hematology Association 2021 Virtual conference.
Read More
Axi-Cel Outperforms Alternate Treatments in R/R Follicular Lymphoma
June 14th 2021Axicabtagene ciloleucel improved outcomes for patients with relapsed/refractory follicular lymphoma over currently available therapies, according to data from a comparative analysis of the ZUMA-5 and SCHOLAR-5 trials.
Read More
Naratuximab Emtansine With Rituximab Leads to Durable Responses in R/R DLBCL
June 12th 2021Naratuximab emtansine in combination with rituximab showed deep responses and a duration of response that was not reached in patients with relapsed or refractory diffuse large B-cell lymphoma, according to findings from a phase 2 trial presented during the EHA 2021 Virtual Congress.
Read More
In R/R B-NHL, High Marks Achieved by C-CAR066
June 8th 2021A favorable safety profile and promising efficacy was seen with C-CAR066, a novel 2nd generation chimeric antigen receptor T-cell therapy targeting the CD20 antigen, in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed with prior CD19 CAR T-cell therapy.
Read More
FDA Accepts sNDA for Zanubrutinib for MZL
May 19th 2021The FDA has accepted a supplemental new drug application for zanubrutinib for the treatment of adult patients with marginal zone lymphoma who have received 1 prior anti-CD20-based therapy. The agent was also granted priority review, with a Prescription Drug User Fee Act target action date of September 19, 2021.
Read More
FDA Lifts Partial Clinical Hold on Study of Odronextamab in FL and DLBCL
May 17th 2021Regeneron is resuming enrollment of patients with follicular lymphoma and diffuse large B-cell lymphoma in monotherapy trial of odronextamab after the FDA lifted the partial clinical hold placed on the agent in December 2020.
Read More
Single-Agent Loncastuximab Tesirine Shows Durable Efficacy and Safety in R/R DLBCL Treatment
May 17th 2021The LOTIS-2 phase 2 study of loncastuximab tesirine continued to show durable responses and tolerability in relapsed or refractory patients with DLBCL, according to the most recent published results.
Read More
Liso-Cel for Patients With R/R LBCL Shows Promising Results in Real-World Settings
May 15th 2021Patients with relapsed or refractory aggressive large B-cell lymphoma showed promising results from the administration of lisocabtagene maraleucel in both inpatient and outpatient non–university hospital settings.
Read More
Liso-Cel Efficacy Not Impacted by Prior CD19 Exposure in LBCL
April 25th 2021In an interview with Targeted Oncology, Scott R. Solomon, MD, a medical oncologist with the Blood and Marrow Transplant Program, Leukemia and Cellular Immunotherapy Program at the Northside Hospital Cancer Institute, discussed the efficacy of liso-cel in large B-cell lymphoma patients with prior anti-CD19 exposure and future research.
Read More